PARP1 and neoplasm: As an example, it has been demonstrated in prostate and non-small cell lung cancer cell lines that the PARP inhibitor ABT-888 radiosensitised hypoxic (0.2% oxygen) tumour cells, but which was similar to that observed in normoxic tumour cells [89].